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INTRODUCTION 
 
Ascites is the most common complication of cirrhosis followed by 
hepatic encephalopathy and variceal hemorrhage.1 In the natural history 
of compensated cirrhosis, 50% of patients develop ascites during 10 years 
of follow up.1 It is the most common complication that leads to hospital 
admission. 2 15% of patients with ascites succumb in 1 year and 44% in 5 
years.3 The major complications of ascites are refractory ascites, 
hepatorenal syndrome and spontaneous bacterial peritonitis.  
 
Patients with cirrhosis and ascites show a higher susceptibility to bacterial 
infections mainly because of the inadequate defense mechanisms. The 
most frequent infectious and severe complication that occurs is 
spontaneous bacterial peritonitis (25%), followed by urinary infections 
(20%), pneumonia (15%) and bacteremia (12%) 4  
 
Spontaneous bacterial peritonitis (SBP) is a potentially life-threatening 
complication in cirrhosis and has typically been described in hospitalized 
patients. The prevalence of SBP in hospitalized patients with 
decompensated cirrhosis is 10% - 30%.5-7 and 18% in those with hepatic 
encephalopathy. 8-9 One-third of patients with infected peritoneal fluid do 
not manifest overt signs or symptoms such as fever or abdominal pain at 
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initial presentation.7 Also 7–27% of patients with cirrhotic ascites harbor 
occult peritoneal fluid infection at the time of hospital admission 6,7,10 
 
The incidence of spontaneous bacterial peritonitis in the outpatient setting 
is very low. Therapeutic paracentesis is the recommended treatment for 
patients with ascites that are resistant or refractory to other medical 
treatment. It also reduces the discomfort associated with tense ascites. It 
is usually done on an outpatient basis. The need for ascitic fluid cell count 
and cultures in asymptomatic cirrhotic patients following large-volume 
paracentesis (LVP) remains unclear. Although many of these patients are 
at increased risk for SBP due to their advanced liver disease, low protein 
ascites, and prior episodes of SBP, the need for routine ascitic fluid 
analysis in the outpatient setting remains unclear. 5 
 
American association for study of Liver disease practice guidelines 
recommend testing of ascitic fluid only for cell count and differential 
count for patients undergoing serial outpatient therapeutic paracenteses. 
11-12  Bacterial culture is not necessary in asymptomatic patients 
undergoing serial large volume paracenteses. 
 
Although the outcome with spontaneous bacterial peritonitis (SBP) and 
its variants has improved over the last decade, the in-hospital and 1-yr 
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mortality of patients with SBP remain approximately 30% and 50%, 
respectively.7, 13-14 Because mortality is 20% even in treated spontaneous 
bacterial peritonitis patients, it is important not to miss the diagnosis. 15 
Therefore, a high index of suspicion with a low threshold to perform a 
diagnostic paracentesis is required to make a rapid diagnosis of this 
potentially life-threatening infection in various clinical settings. 
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AIM 
 
The aim of this study was to determine the prevalence and risk factors for  
1) Spontaneous bacterial peritonitis (SBP) 
2) Monomicrobial non-neutrocytic bacterascites (MNB) and  
3) Culture-negative neutrocytic ascites (CNNA)  
in asymptomatic cirrhotic outpatients undergoing therapeutic 
paracentesis.  
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REVIEW OF LITERATURE 
 
Ascitic fluid infection can be classified into five categories based on 
ascitic culture results, polymorphonuclear (PMN) count, and presence or 
absence of a surgical source of infection. An abdominal paracentesis must 
be performed and ascitic fluid must be analyzed before a confident 
diagnosis of ascitic fluid infection can be made. A “clinical diagnosis” of 
infected ascitic fluid without a paracentesis is not adequate.  
 
Table 1: Classification of Ascitic Fluid Infection 
 
Spontaneous bacterial peritonitis 
Monomicrobial non-neutrocytic bacterascites  
Culture-negative neutrocytic ascites  
Secondary bacterial peritonitis  
Polymicrobial bacterascites (needle perforation of the bowel)  
 
Spontaneous bacterial peritonitis: 
Correia and Conn coined the term “spontaneous bacterial peritonitis” in 
1975. Of the three subtypes of spontaneous ascitic fluid infection, the 
prototype is spontaneous bacterial peritonitis. The diagnosis of 
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spontaneous bacterial peritonitis is made when there is a positive 
ascitic fluid culture and an elevated ascitic fluid absolute PMN count 
(i.e., at least 250 cells/mm3 [0.25 × 109/L]) without evidence of an 
intra-abdominal surgically treatable source of infection. 16 Therefore, 
although many patients with spontaneous bacterial peritonitis have a 
focus of infection (e.g., urinary tract infection or pneumonia), the 
diagnosis of spontaneous bacterial peritonitis is still appropriate unless 
the focus requires surgical intervention (e.g., a ruptured viscus). SBP is 
monomicrobial.  
Monomicrobial non-neutrocytic bacterascites: 
The criteria for diagnosis of monomicrobial nonneutrocytic 
bacterascites (MNB) include (1) a positive ascitic fluid culture for a 
single organism, (2) an ascitic fluid PMN count lower than 250 
cells/mm3 (0.25 × 109/L), and (3) no evidence of an intra-abdominal 
surgically treatable source of infection. 17 In the older literature, MNB 
was either grouped with spontaneous bacterial peritonitis or labeled 
“asymptomatic bacterascites.” Because many patients with 
bacterascites have symptoms, the modifier “asymptomatic” seems 
inappropriate. 
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Culture-negative neutrocytic ascites: 
Culture-negative neutrocytic ascites (CNNA) is diagnosed when (1) the 
ascitic fluid culture grows no bacteria, (2) the ascitic fluid PMN count 
is 250 cells/mm3 (0.25 × 109/L) or greater, (3) no antibiotics have been 
given (not even a single dose), and (4) no other explanation for an 
elevated ascitic PMN count (e.g., hemorrhage into ascites, peritoneal 
carcinomatosis, tuberculosis, or pancreatitis) can be identified. 18 This 
variant of ascitic fluid infection seldom is diagnosed when sensitive 
culture methods are used.19  
PATHOGENESIS 
  
The pathogenesis of SBP in cirrhosis is mainly the consequence of 
bacterial translocation (BT). It is a process through which viable or non-
viable bacteria and bacterial products (bacterial DNA or endotoxins) 
cross the intestinal lumen and come into the mesenteric lymph nodes or 
extraintestinal tissues. The BT is a perturbation of the equilibrium 
between the normal intestinal flora and the organism, leading to an 
inflammatory reaction that perpetuates, finally producing infection.  
 
There are some mechanisms that are being proposed to explain BT in 
cirrhosis: the intestinal bacterial overgrowth, the structural and functional 
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alterations of the intestinal mucosal barrier and the deficiencies of the 
local immune response.20-21  
 
Intestinal bacterial overgrowth: 
 
The intestinal bacterial overgrowth plays a key role in BT in cirrhosis and 
is the result of the delayed intestinal transit existing in these patients. It 
seems that the sympathoadrenal stimulation, increased NO synthesis and 
the oxidative stress of the mucosa are the main causes for decreased 
intestinal motility. 22-23 Besides, although normally in the small intestine 
there is a more reduced microbial density compared to that of the colon, 
in cirrhotic patients an increase of the colonization process of the small 
intestine with bacteria from the colon (approx. 30- 50%) is recorded. 23  
 
Intestinal mucosal barrier: 
 
The barrier of the intestinal mucosa includes defence mechanisms of 
secretory or physical type, against the microbial penetration. The 
secretory (first defence) mechanism is realized through the mucus 
secretion, the local immunoglobulins and the bile salts. The mucins are 
glycoproteins secreted by the epithelial cells that form an electro-negative 
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charged layer, and are attached to it, preventing the direct contact 
between the bacteria and the intestinal membrane. 24  
 
Immunoglobulins - particularly IgA - are secreted by plasma cells from 
the lamina propria and have three major roles: 
- Binding to bacteria (that prevents their adhesion to the mucosa and the 
bacterial     
  colonisation); 
- Toxin and microorganism neutralization; 
- Active transport role as IgA-antigen complex from the lamina propria 
back to the  intestinal lumen.  
 
The bile contributes to the local defence of the intestinal mucosa against 
bacterial aggression by decreasing internalisation of enteric bacteria, 
endotoxin neutralisation and inhibition of excess intestinal flora 
proliferation. The bile has a trophic role for the intestinal mucosa and an 
antiadherence effect for bacteria as well. 24 The concentration of bile acids 
in cirrhosis decreases in the intestinal lumen due to the reduced secretion, 
as well as to the increased deconjugation under the influence of the 
intestinal flora. The consequences of bile acid decrease are the facilitation 
of BT and the increasing process of translocation induced by endotoxins. 
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The physical (second defence) mechanism is represented by the intestinal 
epithelium - by its lack of permeability and its antimicrobial peptide 
active production. The structure of the intestinal epithelium with its cell 
junction disposal allows only the passage of very tiny molecules; 
preventing the bacterial or the macromolecular (lipopolysaccharides) 
transport. 24  
 
In hepatic cirrhosis two processes that alter the intestinal mucosa barrier 
occur: increased mucosal permeability (especially in patients with sepsis) 
because of the mucosa oxidative stress, enterocyte mitochondria 
malfunctioning, endotoxaemia, increased NO and proinflammatory 
cytokine level and the mucosal structural changes. The latter include the 
intercellular spaces enlargement, vasodilatation, edema, fibromuscular 
proliferation, decreased villi/crypts ratio, thickened muscularis mucosae 
and inflammation.22, 24 
 
Another intestinal epithelium defence mechanism is the secretion of 
molecules with antimicrobial role (natural antibiotics), which have the 
capacity of destroying the microorganisms. Among these molecules a 
major role is by α-defensins, synthesized as a reaction to the presence of 
bacteria or lipopolysaccharides, and also the lysozyme and secretory 
phospholipase A2. These antimicrobial peptides are synthesized in the 
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Paneth cells localized at the bottom of each intestinal crypt, mostly in the 
jejunal and ileal region. Besides, most epithelial cells from the small 
intestine and the colon can secrete β-defensin - a peptide involved in the 
defence against commensal bacteria. 20, 24 
 
In addition to the mucosal local defence mechanisms (secretory and 
mechanical), there is at the intestine level the gut-associated lymphoid 
tissue (GALT) – considered the best immunologically represented 
“organ” which includes four compartments: 
1- Peyer’s patches;  
2- Lymphocytes from the lamina propria (including the dendritic cells) 
3- Intraepithelial lymphocytes 
4- Mesenteric lymph nodes (MLN) 
 
The structures that form GALT react to the presence of germs from the 
intestinal lumen by intraepithelial lymphocyte proliferation, germinative 
centre appearance in the lymphoid follicles and in the lamina propria and 
an increase of the secreted Ig level. In return, bacteria that form the 
commensal intestinal flora interact with the intestinal epithelium and can 
start up the primary immune response as well as the adaptative one.24, 25 
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The primary immune response is realized through the monocytes and 
dendritic cells from the intestinal mucosa and request some specific 
bacterial ligands recognition (PAMP = pathogen-associated molecular 
pattern) from corresponding receptors existing in most mononuclear cells 
(PRR = pattern recognition receptor). These receptors belong to a group 
named TLR (toll like receptor), the most important being TLR 2, 4 and 9. 
The stimulation of these receptors by bacterial ligands 
(lipopolysaccharides, lipoteichoic acid, peptidoglycans) activates the 
cytokine and chemokine synthesis and the antimicrobial gene 
transcription. The chemokines synthesized by the epithelial cell recruit 
dendritic cells in the mucosa.24 
 
Luminal bacterial antigens are presented to dendritic cells by two 
mechanisms: indirect, using M cells or direct, using local antigen 
presenting cells (APC). M cells are specific cells from the epithelial layer, 
which overtake the antigen by endocytosis and transport it to the dendritic 
cells and local macrophages.24 The direct mechanism consists of the 
takeover of antigens from local APC by emission of pseudopods among 
the epithelial cells. 
 
Then, APC presents the microbial peptides to B and T lymphocytes from 
the intestinal mucosa or from the MLN, by using lymphatic afferent 
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vessels. APC will determine the type of the immune response stimulating 
Th “naïve” lymphocytes followed by their transformation in effector Th1, 
Th2 or mixed phenotype lymphocytes. The bacterial antigen presentation 
to the B lymphocytes determines secretion of IgA (or IgG) with a 
protective role for the intestinal mucosa.24 
 
Another defence mechanism against bacterial aggression is represented 
by the lymphocyte T migration from the Peyer’s patches after their 
exposure to antigen, to the lamina propria and the epithelium, where they 
mature and convert to T cytotoxic lymphocytes. The link between the 
primary immune response and the adaptative one is made by dendritic 
cells, which present bacterial antigens to B and T lymphocytes from the 
submucosa, but can transport them also to the MLN, where they 
determine a local immune response.24 Bacterial destruction from the 
MLN (by mononuclear cells) is not followed by systemic immunity or 
intestinal inflammation. In cirrhosis, because of the local and systemic 
immune deficiencies, the BT process is followed by bacteremia and 
ascitic fluid inoculation. If the ascitic fluid complement level is low, this 
will determine a low bactericidal activity and thus a higher risk of SBP. 24, 
26 The Kupffer cells have a special role in preventing infections in these 
patients. In healthy people, these local macrophages collaborate with 
neutrophils in the process of bacterial extraction from the circulation, 
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followed by their destruction. In patients with hepatic cirrhosis, because 
of intra- and extrahepatic shunts (due to portal hypertension), circulant 
bacteria do not come in contact with Kupffer cells, the result being 
bacteremia with ascitic fluid inoculation.24 Qualitative neutrophil 
abnormalities (decreased phagocytosis capacity), low complement serum 
levels and the decreased function of macrophages’ Fcy receptors can 
favour SBP.24  
 
BACTERIOLOGY 
Escherichia coli, streptococci (mostly pneumococci), and Klebsiella 
cause most episodes of spontaneous bacterial peritonitis and MNB in 
patients who are not receiving selective intestinal decontamination. The 
most apparent difference between the spontaneous forms of ascitic fluid 
infection and the secondary forms (secondary peritonitis and 
polymicrobial bacterascites) is that the former always are 
monomicrobial and the latter usually are polymicrobial.  
Anaerobes have been found in approximately 1% of cases of 
spontaneous bacterial peritonitis and MNB.17, 19 Selective intestinal 
decontamination causes a change in the bacteria isolated from patients 
in whom an ascitic infection develops. Gram-positive organisms 
usually are cultured from the ascitic fluid of these patients. 27  
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Pathogens in Ascitic Fluid Infection17,19 
 Frequency (%) 
Organism SBP Monomicrobial Non-Neutrocytic 
Bacterascites 
          Monomicrobial 
Escherichia coli 37 27 
Klebsiella pneumoniae 17 11 
Pneumococci 12 9 
Streptococcus viridans 9 2 
Staphylococcus aureus 0 7 
Miscellaneous gram-
negative 
10 14 
Miscellaneous gram-
positive 
14 30 
Polymicrobial 1 0 
 
CLINICAL SETTING 
The spontaneous variants of ascitic fluid infection occur only in the 
setting of severe liver disease. The liver disease usually is chronic 
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(cirrhosis), but may be acute (fulminant hepatic failure) or subacute 
(alcoholic hepatitis). Cirrhosis of all causes can be complicated by 
spontaneous ascitic fluid infection. Spontaneous infection of 
noncirrhotic ascites is rare.  
SBP usually occurs at the time of greatest ascites volume, but can be 
present in settings where the fluid is clinically undetectable. Ascites 
appears to be a prerequisite for the development of spontaneous 
bacterial peritonitis.  
SBP in the absence of ascites is extremely unlikely. 28 The majority of 
patients with SBP have severe liver dysfunction. Toledo et al. 
demonstrated that 96% of patients with SBP had either Child-Pugh grade 
B or C.29 
 
SYMPTOMS AND SIGNS 
Although 87% of patients with spontaneous bacterial peritonitis are 
symptomatic at the time the infection is diagnosed, the symptoms and 
signs of infection are often subtle, such as a slight change in mental 
status and require a high index of suspicion.18 Previously, there was 
often delay in diagnosis, which led to considerable mortality and 
morbidity.30 The symptoms and signs manifested in all 3 variants of 
ascitic fluid infection are listed in the table below.  
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Patients with cirrhosis usually have hypothermia; therefore, any 
temperature > 37.80 C should be investigated, unless it is clearly caused 
by flu-like symptoms. Fever caused by SBP is differentiated from that of 
alcoholic hepatitis, in which the ascitic fluid neutrophil count is normal.30   
 
Alterations in mental status may be subtle occurring in 50% 17, 33 and only 
apparent to someone close to the patient. Abdominal pain can be 
continuous and is different from tense ascites. Tenderness is a common 
feature. 
Symptoms and Signs of Ascitic Fluid Infection17,18, 31, 32 
  Frequency (%) 
Symptom or Sign SBP Bacterascites CNNA
Fever 68 57 50 
Abdominal pain 49 32 72 
Abdominal tenderness 39 32 44 
Rebound tenderness 10 5 0 
Altered mental status 54 50 61 
 
Paralytic ileus, hypotension and hypothermia are seen in advanced 
illness, where prognosis may be dire. Shock at the time of presentation is 
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a rare event 29, probably as a result of the current lower threshold to 
perform diagnostic paracentesis and earlier diagnosis.  Decrements in 
renal function are seen in one-third of cases.34 Thirteen percent of patients 
have no signs or symptoms.30  
 
Without prompt paracentesis, the diagnosis and treatment of infected 
ascites may be delayed, often resulting in the death of the patient. A 
‘diagnostic tap’ should be performed in all patients with ascites admitted 
to hospital. SBP in outpatients with cirrhotic ascites is less frequent, 
occurs in patients with less advanced liver disease, and may have a better 
outcome than its counterpart in hospitalized patients.12   
 
PREVALENCE 
Since the 1980s, routine paracenteses on hospitalization in patients with 
ascites have provided data regarding the prevalence of ascitic fluid 
infection. In the 1980s, approximately 10% of patients with ascites 
were infected at the time of hospital admission; of the subgroup of 
patients with cirrhosis, about 27% were infected.35 At present, because 
of measures to prevent spontaneous bacterial peritonitis, the prevalence 
has dropped significantly.  
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Of patients with culture-positive ascitic fluid, about two thirds have 
neutrocytic ascitic fluid (spontaneous bacterial peritonitis), and one 
third have MNB.17 The frequency of CNNA depends largely on the 
culture technique.  
 
 
RISK FACTORS 
The predisposing factors for SBP are severity of the liver disease, 
decreased protein and C3 level in the ascitic fluid, acute gastrointestinal 
bleeding, urinary tract infection, iatrogenic factors and previous SBP 
episodes. From these factors, the most important one is the severity of 
liver disease: about 70% of the patients which develop SBP are in Child 
C class. Besides, serum bilirubin level >2.5 mg/dl is an independent 
predictive factor of SBP.25   
 
The low bactericidal activity of the ascitic fluid, demonstrated by a 
protein concentration <1g/dl, can favour SBP. Bacteriuria, frequent 
mostly in female cirrhotic patients, can be another factor that favours 
SBP; this is why screening and treatment of urinary infections have to be 
performed even in asymptomatic patients, and urinary catheterization 
must be avoided. 
 20
 
Regarding acute gastrointestinal bleeding, it has been ascertained that 
approx. 20% of the patients have SBP at the time of admission to the 
hospital and 30-40% develop bacterial infections during hospitalization 
for digestive hemorrhage – a possible explanation being that the 
hemorrhagic shock increases BT and intestinal permeability. Also for 
preventing bacteremia, vascular catheterization has to be reduced to a 
minimum. It has been documented that SBP surviving patients have an 
increased risk to recurrence.4, 21  
DIAGNOSIS 
Timely diagnosis of ascitic fluid infection requires a high index of 
suspicion and a low threshold for performing a paracentesis. The main 
indications for paracentesis in a patient with hepatic cirrhosis include: 
unexplained clinical deterioration, the onset of complications (hepatic 
encephalopathy and gastrointestinal bleeding), new onset ascites and at 
every hospitalization. Paracentesis should be avoided only in case of a 
suspicion of fibrinolysis or DIC.4 Although patients with cirrhosis have 
coagulation disturbances, the paracentesis is associated with a very low 
risk of complications: abdominal wall hematoma (1%), 
hemoperitoneum (0,1%) and iatrogenic infections (0,1%). 
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If the ascitic fluid PMN count is elevated, the working diagnosis is 
ascitic fluid infection until proved otherwise. Although peritoneal 
carcinomatosis, pancreatitis, hemorrhage into ascites, and tuberculosis 
can lead to an elevated ascitic fluid PMN count, most cases of 
neutrocytic ascites are caused by bacterial infection. A predominance 
of PMNs in the WBC differential count lends further credence to the 
diagnosis of infection.  
Although spontaneous bacterial peritonitis is approximately six times 
as common as surgical peritonitis in a patient with ascites, secondary 
peritonitis should be considered in any patient with neutrocytic ascites. 
Clinical symptoms and signs do not distinguish patients with secondary 
peritonitis from those with spontaneous bacterial peritonitis.31 Even 
with free perforation of the colon into ascitic fluid, a classic surgical 
abdomen does not develop. Peritoneal signs require contact of inflamed 
visceral and parietal peritoneal surfaces, and such contact does not 
occur when there is a large volume of fluid separating these surfaces.  
After paracentesis, the ascitic fluid should be inoculated immediately (at 
the patient‘s bedside) into blood-culture bottles (10ml in each bottle) that 
increases the diagnosis rate from 50 to 80%. Because almost half the SBP 
cases are associated with bacteremia and any bacterial infection in 
cirrhotic patients can lead to manifestations similar to SBP, blood and 
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urine cultures from these patients are useful.4 The chest x-ray can show a 
right hydrothorax. If infection is suspected (and SBP diagnosis has been 
ruled out), thoracentesis is necessary in order to establish diagnosis 
because the spontaneous bacterial empyema can occur even without 
ascites or SBP.  
The best time to repeat the paracentesis to assess the response to 
treatment is after 48 hours of therapy; by 48 hours, the ascitic PMN 
count will be lower than the pretreatment value and the ascitic culture 
will be negative in essentially every patient with spontaneous bacterial 
peritonitis who has received treatment with an appropriate antibiotic.31 
Whereas antibiotics alone cannot control secondary peritonitis, medical 
therapy rapidly cures spontaneous bacterial peritonitis. 31 
TREATMENT 
 
Many years ago, the usual treatment for cirrhotic patients with ascites and 
SBP was the combination of a β-lactam plus an aminoglycoside. Because 
patients with SBP are very sensitive to the nephrotoxicity associated with 
use of aminoglycosides, this initial treatment scheme has been replaced 
with a third generation cephalosporin -Cefotaxim. It has been shown in a 
controlled trial to be superior to ampicillin plus tobramycin for the 
treatment of spontaneous bacterial peritonitis.36 Fully 98% of causative 
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organisms were susceptible to cefotaxime, which did not result in 
superinfection or nephrotoxicity.36  
 
Cefotaxime or a similar third-generation cephalosporin appears to be the 
treatment of choice for suspected spontaneous bacterial peritonitis.35 
Cefotaxime, 2 g intravenously every 8 hours, has been shown to result in 
excellent ascitic fluid levels (20-fold killing power after one dose).37 In 
patients with a serum creatinine level greater than 3 mg/dL, the dosing 
interval may be extended to 12 hours. Neither a loading dose nor an 
intraperitoneal dose appears to be necessary or appropriate. The clinician 
should, however, write “first dose STAT” when ordering treatment, to 
avoid a delay in administration of the life-saving agent. 
 
In patients with uncomplicated SBP (no gastrointestinal bleeding, hepatic 
encephalopathy, ileus, shock or renal failure), treatment with Ofloxacin or 
other oral quinolones for 8 days can be administrated. 38-41 A good 
response to therapy can be evaluated by clinical criteria (disappearance of 
signs and symptoms of infection), but the most important parameter 
remains the decrease to a half (from the pre-treatment value) of the PMN 
number in the ascitic fluid obtained by paracentesis after two days of 
treatment.42 Studies that require further confirmation propose the addition 
of albumin (1.5 g/kg body weight the first day, then 1g/kg three more 
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days) to the Cefotaxime treatment for patients with renal failure and SBP. 
Albumin in these patients may improve the renal function by increasing 
the intravascular volume, because vasodilatation induced by cytokines 
released in excess reduces the effective arterial volume.40, 43 
Patients with cirrhotic ascites who have convincing symptoms or signs of 
infection should receive treatment regardless of the ascitic fluid PMN 
count. Empirical treatment can be discontinued after only 2 to 3 days if 
the culture demonstrates no growth. Asymptomatic patients may not need 
treatment.35, 42 The paracentesis should be repeated for cell count and 
culture in patients without clinical evidence of infection, once it is known 
that the initial culture result is positive. If the PMN count has risen to at 
least 250/mm3 (0.25 × 109/L) or if symptoms or signs of infection have 
developed, treatment should be started. Culture results usually are 
negative in patients without a rise in the ascitic fluid PMN count on 
repeat paracentesis and without clinical evidence of infection, and these 
persons do not require treatment, because colonization has been 
eradicated by host immune defenses. If the clinical picture initially is 
unclear, the physician should err on the side of antibiotic treatment (with 
a non-nephrotoxic antibiotic).  
Other adjuvant therapies in patients with SBP include prokinetics and 
probiotics. Prokinetics are used to shorten the intestinal transit time, 
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reducing thus the intestinal bacterial overgrowth and the risk of bacterial 
translocation. Encouraging results have been obtained by using Cisapride 
and Propranolol, the latter’s β blocking effect antagonises the increased 
adrenergic tone existent in patients with cirrhosis and responsible for the 
decreased intestinal motility. 
 
Probiotics are used for intestinal flora reequilibration, in favour to 
anaerobic protective bacteria. Bacteriotherapy with Lactobacillus seems 
to correct intestinal bacterial overgrowth, to stabilize mucosal barrier 
function and to stimulate the local defence mechanisms. 4, 24 Oral 
treatment with conjugated bile acids (cholylglycine and cholylsarcosine) 
for preventing BT is under evaluation. 24 
The decision to begin empirical antibiotic treatment in patients with 
bacterascites must be individualized. Many episodes resolve without 
treatment. The hospital mortality rate of 32% in patients with MNB is 
attributable at least in part to infection, however.17 Therefore, treatment 
appears to be warranted in many patients. By definition, the ascitic PMN 
count is lower than 250 cells/mm3 in this variant of ascitic fluid infection 
and the PMN count cannot be the only parameter on which to base the 
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Table 4: Treatment of Subtypes of Ascitic Fluid Infection  
 
Diagnosis Treatment 
Spontaneous 
bacterial peritonitis 
Five days of intravenous antibiotic to which the 
organism is highly susceptible (e.g., cefotaxime 2 
g q8h empirically followed by more specific 
therapy after susceptibility results are available) 
Monomicrobial non-
neutrocytic 
bacterascites 
Five days of intravenous antibiotic to which the 
organism is highly susceptible, if the patient is 
symptomatic or persistently culture-positive; not 
all patients with bacterascites require treatment 
Culture-negative 
neutrocytic ascites 
Five days of intravenous third-generation 
cephalosporin (e.g., cefotaxime 2 g q8h) 
 
decision about empirical therapy. Most patients with MNB in whom the 
colonization does not resolve progress to spontaneous bacterial 
peritonitis and have symptoms or signs of infection at the time of the 
paracentesis that documents bacterascites.17 
The physician will not know initially that the ascitic fluid culture is 
destined to be negative in a patient with CNNA; therefore, empirical 
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antibiotic treatment should be started. When the preliminary culture 
demonstrates no growth, it is helpful to repeat the paracentesis after 48 
hours of therapy to assess the response of the PMN count to antibiotics. 
A dramatic decline in PMN count (always below the baseline 
pretreatment value and frequently a greater than 80% reduction) confirms 
a response to treatment. In such cases, a few more days of therapy 
probably is warranted. A stable ascitic fluid PMN count, especially with 
a predominance of lymphocytes and monocytes, suggests a nonbacterial 
(or mycobacterial) cause of ascitic fluid neutrocytosis, and the fluid 
should be sent for cytologic examination and mycobacterial culture. 
Because a negative culture result may be due to insensitive culture 
techniques, the prevalence of CNNA in a hospital that still uses 
conventional methods of culture can be reduced by convincing the 
microbiology laboratory to accept and process ascitic fluid submitted in 
blood culture bottles.44  
Until the results of susceptibility testing are available, relatively broad-
spectrum antibiotic therapy is warranted in patients with suspected ascitic 
fluid infection. After sensitivities are known, the spectrum of coverage 
usually can be narrowed.  
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Other Intravenous Antibiotics  
Amoxicillin–clavulanic acid has been shown to be as effective as 
cefotaxime in a randomized trial.45 Other antibiotics have been 
recommended as well but have been less well studied than has 
cefotaxime. Some newer drugs have been used to treat spontaneous 
bacterial peritonitis (without any data on antibiotic penetration into the 
ascitic fluid) on the basis of their spectrum of coverage and formulary 
constraints. Infection with organisms that are resistant to the empirical 
anti-biotic or use of drugs that do not enter the ascitic fluid in high 
enough concentrations to kill the bacteria may lead to death. 
Oral Antibiotic Treatment  
Oral ofloxacin has been reported in a controlled trial to be as effective as 
parenteral cefotaxime in the treatment of spontaneous bacterial peritonitis 
in patients who are not vomiting, in shock, bleeding, or in renal failure.46 
The dose studied was 400 mg twice daily. 46 Another study has 
demonstrated the efficacy of intravenous ciprofloxacin, 200 mg every 12 
hours for 2 days, followed by oral ciprofloxacin, 500 mg every 12 hours 
for 5 days. 47  
Because of the possibility of fluoroquinolone resistance in patients 
receiving fluoroquinolones to prevent spontaneous bacterial peritonitis, 
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however, the empirical use of a fluoroquinolone to treat suspected 
spontaneous bacterial peritonitis should be avoided. Fortunately, bacterial 
isolates from patients with spontaneous bacterial peritonitis who were 
receiving fluoroquinolones for prophylaxis of this disorder remain 
susceptible to cefotaxime.42  
DURATION OF TREATMENT 
Infectious disease subspecialists generally recommend 10 to 14 days of 
antibiotic therapy for life-threatening infections. No data are available to 
support this duration of treatment in spontaneous ascitic fluid infections, 
however. The ascitic fluid culture becomes sterile after one dose of 
cefotaxime in 86% of patients.31 After 48 hours of therapy, the ascitic 
fluid PMN count is always less than the pretreatment value in patients 
with a spontaneous ascitic fluid infection treated with appropriate 
antibiotics; frequently, an 80% reduction is observed at 48 hours. 31  
A randomized, controlled trial involving 100 patients has demonstrated 
that 5 days of treatment is as efficacious as 10 days in the treatment of 
spontaneous bacterial peritonitis and CNNA.48 The average duration of 
oral ofloxacin treatment was 8 days in the only published trial.46  
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Narrowing the Spectrum of Coverage  
After the results of susceptibility testing are available, an antibiotic with a 
narrower spectrum of activity usually can be substituted for the broad-
spectrum drug (e.g., pneumococci usually will be sensitive to penicillin, 
and most E. coli species usually will be sensitive to ampicillin). 
Intravenous Albumin  
Renal impairment occurs in 33% of episodes of spontaneous bacterial 
peritonitis.34 Spontaneous bacterial peritonitis leads to increased 
intraperitoneal nitric oxide production, which in turn further increases 
systemic vasodilatation and promotes renal failure.49 Intravenous albumin 
(1.5 g/kg of body weight at the time the infection is detected and 1.0 g/kg 
on day 3) can increase intravascular volume and, in combination with 
cefotaxime, has been shown in a large randomized trial to reduce the risk 
of renal failure and improve survival compared with cefotaxime without 
albumin.50 Because of the survival advantage, however, the use of 
intravenous albumin as an adjunct to antibiotic treatment has been 
recommended.51  
EMPIRIC TREATMENT 
Patients with ascitic fluid PMN counts of 250 cells/mm3 in a clinical 
setting compatible with ascitic fluid infection should receive empiric 
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antibiotic therapy.16, 30 The ascitic fluid PMN count is more rapidly 
available than the culture and appears to be accurate in determining who 
really needs empiric antibiotic treatment. 16, 30 Delaying treatments until 
the ascitic fluid culture grows bacteria may result in the death of the 
patient from overwhelming infection.  
 
In some patients, infection is detected at the bacterascites stage before 
there is a neutrophil response. Most patients resolve the colonization 
without antibiotics and without a neutrophil response.17 An elevated 
ascitic fluid PMN count probably represents evidence of failure of the 
first line of defense, the peritoneal macrophages, to kill invading bacteria. 
Patients with bacterascites who do not resolve the colonization and who 
progress to SBP have signs or symptoms of infection at the time of the 
paracentesis that documents bacterascites.17, 27 
 
The majority of patients with culture-positive neutrocytic ascites 
demonstrate rising bacterial counts and rising PMN counts when serial 
samples are obtained in rapid sequence before initiation of antibiotic 
therapy.27Patients with culture-negative neutrocytic ascites have similar 
signs, symptoms, and mortality as patients with SBP and warrant empiric 
antibiotic treatment.18 The majority of patients with culture-negative 
neutrocytic ascites continue with this pattern of ascitic fluid analysis 
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when serial samples are obtained in rapid sequence before initiation of 
antibiotic therapy; 34.5% become culture-positive.17 
 
The patient with alcoholic hepatitis may have fever, leukocytosis, and 
abdominal pain that can masquerade as SBP. In addition, they can 
develop SBP. These patients do not develop false-positive elevated ascitic 
fluid PMN counts because of peripheral leukocytosis52; an elevated PMN 
count must be presumed to represent SBP. Empiric antibiotic treatment 
(for presumed ascitic fluid infection) of patients with alcoholic hepatitis 
who have fever and/or peripheral leukocytosis can be discontinued after 
48 hours if ascitic fluid, blood, and urine cultures demonstrate no 
bacterial growth. 
 
Relatively broad-spectrum therapy is warranted in patients with suspected 
ascitic fluid infection until the results of susceptibility testing are 
available. Cefotaxime, a third-generation cephalosporin, has been shown 
to be superior to ampicillin plus tobramycin in a controlled trial.36 
Cefotaxime or a similar third-generation cephalosporin appears to be the 
treatment of choice for suspected SBP; it covers 95% of the flora 
including the three most common isolates: Escherichia coli, Klebsiella 
pneumoniae, and pneumococci. 36 Widespread use of quinolones to 
prevent SBP in high-risk subgroups of patients has led to a change in 
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flora with more gram-positives and quinolone-resistant bacteria in recent 
years.53   
 
PREVENTION OF SBP 
Certain subgroups of patients with cirrhosis and ascites are at increased 
risk for the development of SBP, including those with: (1) upper 
gastrointestinal bleeding, (2) prior episodes of SBP, and (3) low protein 
(<1 g/dl) ascites. The identification of risk factors for development of 
SBP has led to randomized controlled trials of prophylactic antibiotics.5, 
54-59  
 
Norfloxacin 400 mg/day orally has been reported to successfully prevent 
SBP.54-55 Patients with digestive tract hemorrhage are more at risk in 
developing SBP; it is considered that 20% of them have SBP at admission 
and 30-40% will develop an infection during hospitalization. Norfloxacin 
400 mg orally twice per day for 7 days helps prevents infection in 
patients with variceal hemorrhage.56A group in France reported a 
reduction in hospitalization mortality for patients with variceal 
hemorrhage from 43% 20 years ago to 15% recently; much of the reduced 
mortality was attributed to use of antibiotics to prevent infections.60 An 
antibiotic can be given intravenously while the patient is actively 
bleeding; ofloxacin (400 mg/day) has been validated for this purpose.57 A 
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meta-analysis of five trials in patients with cirrhosis and gastrointestinal 
bleeding has shown a survival advantage of 9.1% in the treated group.61 
 
Parenteral antibiotics to prevent sclerotherapy-related infections do not 
appear to be warranted, based on a controlled trial.62 It is the active 
bleeding that appears to be the risk factor for infection, not 
sclerotherapy.63 Variceal banding has largely replaced sclerotherapy; 
antibiotics would be even less likely to be of benefit in the setting of 
banding. 
 
The use of selective intestinal decontamination (SID) with norfloxacin in 
patients admitted to the hospital with low-protein ascites has also shown a 
reduction in the incidence of SBP from 22.5 to 0%.56 Selective intestinal 
decontamination with norfloxacin or trimethoprim/ sulfamethoxazole in 
patients with prior SBP or low protein ascitic fluid does appear to be cost-
effective.64-65 Also selective intestinal decontamination does select 
resistant gut flora, which can subsequently cause spontaneous infection; 
fortunately, infection-causing bacteria that are resistant to quinolones are 
usually sensitive to cefotaxime.66 Patients who develop SBP on quinolone 
prophylaxis should not receive these drugs for treatment but instead 
undergo treatment with a third-generation cephalosporin (i.e. 
cefotaxime).46-47, 67 
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Other prophylactic measures include:  
1) Diuretics, which reduce the ascites volume and increase the ascitic 
fluid opsonic activity 5,68, 69 
2) Local infections treatment and eradication, before their 
dissemination 
3) Screening for and prophylaxis of esophageal varices to reduce the 
risk of gastrointestinal hemorrhage are also recommended.  
4) Porto-caval shunts and TIPS (transjugular intrahepatic 
portosystemic shunt) for digestive hemorrhage or ascites risk 
reduction, reducing indirectly SBP risk 
5) Abstinence from alcohol in case of alcoholic cirrhosis. 
 
Patients surviving an episode of SBP should be considered for liver 
transplantation if acceptable candidates.42 Regardless, antibiotic 
prophylaxis should be restricted to high-risk patients; namely those with 
gastrointestinal hemorrhage (short-term), a prior episode of SBP (long-
term), or those with ascitic fluid total protein levels < 1 g/dl.35 Whether 
the latter group should receive long-term or inpatient-only prophylaxis 
needs careful assessment of the risks and benefits on a case-by-case basis. 
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FOLLOW-UP PARACENTESIS 
A follow-up ascitic fluid analysis is not needed in many patients with 
infected ascites.70 Repeat paracentesis can be performed to document 
sterility of culture and dramatic decrease in PMN count in patients with 
SBP; however, it is not necessary. The majority of patients have SBP in 
the typical setting (i.e., advanced cirrhosis) with typical symptoms, 
typical ascitic fluid analysis (total protein of 1 g/dL, LDH less than the 
upper limit of normal for serum, and glucose of 50 mg/dL), a single 
organism, and a dramatic clinical response.30,70  
 
In contrast, if the setting, symptoms, analysis, organism(s), or response 
are atypical, repeat paracentesis can be helpful in raising the suspicion of 
secondary peritonitis and prompting further evaluation and surgical 
intervention when appropriate.31 
PROGNOSIS 
In the past, 48% to 95% of patients with a spontaneous ascitic fluid 
infection died during the hospitalization in which the diagnosis was 
made, despite antibiotic treatment. 28, 35 The most recent series report the 
lowest mortality rates (less than 5% if antibiotics are administered in a 
timely fashion), probably because of earlier detection and treatment of 
infection, as well as the avoidance of nephrotoxic antibiotics.71 In order 
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to maximize survival, it is important that paracentesis be performed in all 
patients with ascites at the time of hospitalization, so that infection can be 
detected and treated promptly. 
The trial in which cefotaxime plus albumin was studied reported the 
lowest hospitalization mortality rate yet—10%.50 Even now, however, 
some patients are cured of their infection but die of liver failure or 
gastrointestinal bleeding, because of the severity of the underlying liver 
disease. In fact, spontaneous ascitic fluid infection is a good marker of 
end-stage liver disease and has been proposed as an indication for liver 
transplantation in a patient who is otherwise a candidate. 
Paracentesis should be repeated during the hospitalization if any 
manifestation of clinical deterioration develops, including abdominal 
pain, fever, change in mental status, renal failure, acidosis, peripheral 
leukocytosis, or gastrointestinal bleeding. No survivors of spontaneous 
bacterial peritonitis have been reported when the diagnosis is made after 
the serum creatinine level has risen above 4 mg/dL (350 μmol/L) or after 
shock has developed. 
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MATERIALS AND METHODS 
It was a prospective study between January 2008 and December 2009 
where consecutive asymptomatic outpatients with cirrhosis undergoing 
therapeutic paracentesis for tense ascites were included. The same patient 
undergoing paracentesis on more than one occasion was also included. 
All patients had a baseline ascitic fluid analysis. Cirrhosis was diagnosed 
by clinical, imaging and biochemical values. Baseline demographic 
details including age, gender, literacy and socioeconomic status were 
collected. A detailed work up for the etiology of cirrhosis was done. The 
severity of liver disease was graded according to Child Pugh scoring.  
 
Ascitic fluid paracentesis was performed in the standard fashion by 
means of an 18-Fr catheter connected to a line and draining by gravity. 
The ascitic fluid was collected under strict aseptic precautions for 
analysis. Ascitic fluid total white cell count along with the differential 
count was performed using standard laboratory techniques. Laboratory 
analysis for estimation of total protein and albumin levels was done. 
Bacterial cultures were obtained by bedside inoculation of 10 mL of 
ascitic fluid into aerobic and anaerobic blood culture bottles under strict 
aseptic precautions.  
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The diagnosis of Spontaneous bacterial peritonitis was made when there 
was a positive ascitic fluid culture and an elevated ascitic fluid absolute 
PMN count (i.e., at least 250 cells/mm3 [0.25 × 109/L]) without evidence 
of an intra-abdominal surgically treatable source of infection.16  
 
The criteria for diagnosis of Monomicrobial nonneutrocytic 
bacterascites (MNB) included (1) a positive ascitic fluid culture for a 
single organism, (2) an ascitic fluid PMN count lower than 250 cells/mm3 
(0.25 × 109/L), and (3) no evidence of an intra-abdominal surgically 
treatable source of infection.17 
 
Culture-negative neutrocytic ascites (CNNA) was diagnosed when (1) 
the ascitic fluid culture grows no bacteria, (2) the ascitic fluid PMN count 
is 250 cells/mm3 (0.25 × 109/L) or greater, (3) no antibiotics have been 
given (not even a single dose), and (4) no other explanation for an 
elevated ascitic PMN count (e.g., hemorrhage into ascites, peritoneal 
carcinomatosis, tuberculosis, or pancreatitis) 
Exclusion criteria: 
Patients excluded were those with  
1) Fever  
2) Abdominal pain 
3) Hepatic encephalopathy 
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4) Gastrointestinal bleeding within the last month  
5) Impaired renal function 
6) Previous history of SBP and  
7) Antibiotic treatment within 2 weeks 
8) Antibiotic prophylaxis for SBP 
9) Noncirrhotic ascites 
 
Patients with diagnosis of SBP were hospitalized for treatment while 
those with neutrocytic ascites and monomicrobial bacterascites were 
treated with oral antibiotics Ofloxacin 400 mg twice a day for 5 days.18 A 
follow up paracentesis was done to confirm the resolution of the 
infection. 
 
All patients who participated in the study gave a written informed 
consent. The study was approved by the institutional ethical committee.  
 
Statistical analysis:  
Quantitative data were expressed in Mean & SD. Qualitative data were 
given in frequencies with their percentage. The association between 
various factors like age, gender, alcohol consumption, etiology of 
cirrhosis, Child’s score, serum albumin and mean ascitic fluid total 
protein study and the occurrence of ascitic fluid infection was analyzed 
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using Pearson Chi square test/ student independent test/2 sample 
proportion test as appropriate. P<0.05 was taken as statistically 
significant. 
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RESULTS 
A total of 110 patients with cirrhosis underwent therapeutic paracentesis 
in the outpatient setting during the study period. The mean age of the 
study population was 47.1+9.6 years. Cirrhosis was predominantly 
observed in men (Male: Female - 2.7:1). The etiology of cirrhosis was: 
1) Alcohol in 55.5%. 
2) Hepatitis B in 21.8% 
3) Hepatitis C in 9.1% and  
4) Miscellaneous in 13.6%. 
 
 
 
 
 
 
 
 
The severity of liver disease as assessed by Child Pugh scoring was: 
Child’s B and C in 70% and 30% respectively. Total number of 
paracentesis performed during the study period was 278 with a range 
between one and four. The average number of paracentesis was 2.5+1.1. 
The characteristics of the study population are summarized in Table 1. 
 Etiology of Cirrhosis
Alcohol
Hepat it is B
Hepat it is C
Miscellaneous
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Table 1: Demographic characteristics of the study population 
 
Characteristics No (%) 
Total No of cases 110 
Mean age (years) 47.1+9.6 
Gender distribution  
Male 80 (72.7) 
Female 30 (27.3) 
Literacy status  
Yes 36 (32.7) 
No 74 (67.3) 
Etiology of cirrhosis  
Alcohol 61 (55.5) 
Hepatitis B 24 (21.8) 
Hepatitis C 10 (9.1) 
Miscellaneous 15 (13.6) 
Child Turcotte Pugh staging (CTP)  
CTP B 77 (70) 
CTP C 33 (30) 
Total No of paracentesis 278 
Average paracentesis 2.5+1.1 
 
The prevalence of spontaneous ascitic fluid infection in asymptomatic 
cirrhotic patients undergoing therapeutic paracentesis was 2.5% (7/278 
paracentesis). The variants of ascitic fluid infection observed were: 
1) Spontaneous bacterial peritonitis in one (0.4%), 
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2) Monomicrobial nonneutrocytic bacterascites in two (0.7%) and  
3) Culture-negative neutrocytic ascites in four patients (1.4%). 
 
The characteristic of patients with ascitic fluid infection is shown in 
Table 2. The bacterial culture showed Escherichia coli in one patient with 
spontaneous bacterial peritonitis. Klebsiella and Staphylococcus aureus 
were grown in patients with bacterascites. All patients had evidence of 
spontaneous infection at the time of their first therapeutic paracentesis.  
 
There was no significant difference between outpatient cirrhosis with and 
without infection with regards to age (p=0.73), gender (p=0.93), alcohol 
consumotion (p=1), etiology of cirrhosis (p=0.93), Child Pugh score 
(p=0.93), serum albumin (p=1) and ascitic fluid total protein (p=0.19). 
[Table 3] 
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Table 2: Characteristics of patients with ascitic fluid infection 
 
 
Cases Age Sex Etiology Childs  
staging 
Alcohol Total  
no of 
paracentesis
Cell 
count
>250 
cells/ 
mm3
Culture Serum 
albumin
  
(gm/dl) 
Ascitic 
protein 
 
(gm/dl)
1 52 M Alcohol B Yes 1 No Positive 2.6 1 
2 49 M HBV C No 4 No Positive 3.1 1.3 
3 48 F HCV C No 3 Yes Negative 2.3 1.1 
4 47 M Alcohol B Yes 3 Yes Negative 3 1.2 
5 48 M Alcohol B Yes 3 Yes Negative 3 1.2 
6 47 M Alcohol B Yes 2 Yes Negative 2.8 1 
7 47 F Others B No 2 Yes Positive 2.9 1 
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Table 3: Cirrhosis with and without spontaneous ascitic fluid infection 
 
 Outpatients with Ascitic  Fluid 
infection 
P 
value 
Yes 
N=7 (2.5%) 
No 
N=103 (97.5%) 
Mean Age (years) 48.3+1.8 47+9.9 0.73 
Gender Male 5 (71.4) 75 (72.8) 0.93 
Female 2 (28.6) 28 (27.2) 
Alcohol 4 (57.1) 57 (55.3) 1 
 
 
Etiology 
Alcohol 4 (57.1) 57 (55.3) 0.93 
Hepatitis B 1 (14.3) 23 (22.3) 
Hepatitis C 1 (14.3) 9 (8.7) 
Miscellaneous 1 (14.3) 14 (13.6) 
Child’s 
score 
B 5 (71.4) 72 (69.9) 0.93 
C 2 (28.6) 31 (30.1) 
Serum albumin 2.8+0.3 2..8+0.4 1 
Mean ascitic fluid 
protein 
1.1+0.1 1.2+0.2 0.19 
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DISCUSSION 
 
SBP in asymptomatic outpatients has distinguishing features from SBP in 
hospitalized patients and may be a separate entity. The organisms 
cultured are predominantly gram positive in outpatients as compared with 
gram negative in hospitalized patients. Survival is better, and type I 
hepatorenal syndrome as a complication of SBP in outpatients is 
infrequent, whereas type I hepatorenal syndrome occurs in as many as 
30% of inpatients with SBP.50 Finally, recurrence of SBP is unusual in 
outpatients even when they are not on antibiotic prophylaxis. Only one 
third of the outpatients diagnosed with SBP died within 1 year of the 
outpatient paracentesis as compared with a 1-year mortality of 50% to 
70% in historically hospitalized patients with SBP.72 
 
Several retrospective studies of inpatients have demonstrated poor 
performance of clinical signs in the diagnosis of spontaneous bacterial 
peritonitis. Fever, abdominal pain, and encephalopathy were present in 
32% - 54%, 41% - 57%, and 9% - 74% of spontaneous bacterial 
peritonitis patients, respectively.73-75 In clinical practice, patients 
requiring therapeutic LVP may present with less ominous but concerning 
symptoms of vague abdominal discomfort, mild tenderness on exam, or 
subtle changes in affect that may be suggestive of occult infection. The 
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pain related to the abdominal wall distention of large volume ascites in 
the non–spontaneous bacterial peritonitis patient may be difficult to 
differentiate from peritoneal irritation in the spontaneous bacterial 
peritonitis.  
 
Brian Chinnock et al 76 concluded that clinical signs, symptoms, and 
physician impression were poor in ruling out spontaneous bacterial 
peritonitis. Abdominal pain or tenderness was unreliable in the diagnosis 
of spontaneous bacterial peritonitis in patients undergoing diagnostic or 
therapeutic paracentesis in the emergency department. 
 
It would be reasonable in such instances of clinical uncertainty to obtain 
ascitic fluid cell count with differential. This approach would rapidly 
screen for SBP and CNNA, which require immediate intervention without 
the additional expense of cultures. However, if the ascitic fluid were 
cloudy at the time of therapeutic paracentesis, it would be prudent to 
obtain not only cell counts but a bacterial culture as well. 
 
The incidence of SBP in cirrhotic outpatients undergoing large volume 
paracentesis (LVP) with low risk of infection is very low. Evans et al.12 
found the prevalence of SBP to be 1.4% and neutrocytic ascites to be 
2.1% in 427 paracenteses in 427 cirrhotic patients seen at a single 
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outpatient clinic without symptoms of SBP and without high risk of SBP. 
The prevalence of bacterascites was 3% which was frequent in patients 
on selective intestinal decontamination. Mark A. Jeffries et al11 
prospectively studied ascitic fluid cell counts and cultures in outpatients 
with refractory ascites undergoing large volume paracentesis. 2.5% had 
monomicrobial bacteriascites. None had spontaneous bacterial peritonitis.   
 
In our study, the prevalence of spontaneous bacterial peritonitis in 
asymptomatic cirrhotics undergoing therapeutic paracentesis was 0.4%. 
Monomicrobial nonneutrocytic bacterascites and Culture-negative 
neutrocytic ascites were observed in 0.7% and 1.4% respectively. 
 
Two other studies have addressed the issue of whether ascitic fluid should 
be analyzed at the time of therapeutic paracentesis in asymptomatic 
outpatients. In a retrospective study of 37 outpatient LVPs performed at 
Emory University, ascitic fluid cell counts and cultures revealed no 
evidence of peritoneal fluid infection.77 Similarly, in a prospective study 
from Barcelona, 173 ascitic fluid samples were analyzed from 51 
asymptomatic stable cirrhotics with Refractory ascites (RA).78All ascitic 
fluid cell counts were < 250 PMN/mm3 and only four cultures (2.3%) 
grew bacterial microorganisms and were classified as asymptomatic 
MNB. 
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Runyon recently reported a 2% prevalence of spontaneous bacterial 
peritonitis in a series of 400 paracenteses performed in two years in an 
outpatient setting.35 A retrospective review of 916 outpatient AF samples 
from the United States showed that abnormal AF appearance had a 
sensitivity of 98.1% [(95% confidence interval (CI): 95.3%-99.5%] and a 
specificity of 22.7% (95% CI: 19.4%-26.3%) in the detection of SBP.79 
For out- and inpatients, laboratory abnormalities such as leukocytosis, 
metabolic acidosis and azotemia, should prompt investigations for SBP, 
even in the absence of other clinical features. 
 
The organisms cultured were unusual and did not include Escherichia 
coli and Klebsiella pneumoniae, which are usually seen in hospitalized 
patients with cirrhosis. They were mostly gram-positive cocci. The 
organisms grown in our study were Escherichia coli, Klebsiella and 
Staphylococcus. A study by Fernandez et al., 53 confirmed the changing 
patterns of organisms cultured from patients with SBP. It was explained 
on the basis of norfloxacin prophylaxis or interventions previously 
carried out.  
 
While patients with ascitic fluid positive for Escherichia coli developed 
clinical SBP after 24 h, those secondary to gram-positive cocci did not 
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develop an overt clinical or analytical SBP. Moreover, a second ascitic 
fluid analysis performed some days after the index episode proved normal 
in all cases. 
 
In our study, the bacterial culture showed Escherichia coli in one patient 
with spontaneous bacterial peritonitis. Klebsiella and Staphylococcus 
aureus were grown in patients with bacterascites. 
 
Patients with neutrocytic ascites did not suffer decreasing liver or renal 
function, or clinical features of SBP despite no treatment suggesting that 
they might represent a false positive of the total PMN count for diagnoses 
of SBP. Several studies have confirmed spontaneous clearance of 
bacterascites on close monitoring of subjects with MNB. 17, 78, 80 As many 
as 62% of episodes of bacterascites resolve without development of 
neutrocytic ascites.17 Because the outcome of patients with asymptomatic 
MNB was favorable, minimal risk would be incurred if ascitic fluid 
cultures were not routinely performed. Also such patients do not require 
antibiotic therapy. 
 
It is unclear whether bacterascites represents true pathogenic growth or 
simple transient colonization of peritoneal fluid with intestinal flora. 
However, another study demonstrated that about one third of 
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bacterascites progressed to spontaneous bacterial peritonitis.17 Studies 
have shown similar in hospital mortality in patients with normal ascitic 
fluid and those with asymptomatic bacterascites, and consensus 
recommendations do not indicate the need for immediate antimicrobial 
treatment of these patients.42, 80 
 
Although further studies are needed, the routine culture of ascitic fluid in 
asymptomatic outpatients frequently receiving prophylactic antibiotics 
may not be necessary when there is a low index of suspicion for occult 
infection. In circumstances of clinical uncertainty, however, obtaining an 
ascitic fluid cell count with differential is recommended to ensure patient 
safety.  
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SUMMARY 
 
In the present study, 
1) The prevalence of Spontaneous bacterial peritonitis in cirrhotic 
outpatients undergoing therapeutic paracentesis is 0.4%. 
2) The prevalence of Monomicrobial nonneutrocytic bacterascites in 
cirrhotic outpatients undergoing therapeutic paracentesis is 0.7% 
3) The prevalence of Culture-negative neutrocytic ascites in cirrhotic 
outpatients undergoing therapeutic paracentesis is 1.4% 
4) There was no significant difference between outpatient cirrhosis 
with and without infection with regards to age, gender, alcohol 
consumption, and etiology of cirrhosis, Child Pugh score, serum 
albumin and ascitic fluid total protein. 
 
 
 
 
 
 
 
 54
CONCLUSION 
 
In conclusion, the results of our study confirm that the prevalence of 
spontaneous bacterial peritonitis, monomicrobial bacterascites and culture 
negative non neutrocytic ascites in asymptomatic cirrhotic outpatients 
undergoing therapeutic paracentesis was very low. There were no 
significant risk factors predicting the occurrence of spontaneous infection 
of the ascitic fluid in outpatients.  
 
In our opinion, routine ascitic fluid analysis may be unnecessary in this 
clinical setting as it may not be cost effective. However testing the ascitic 
fluid only for cell count and differential in outpatient therapeutic 
paracenteses will ensure the clinician not to miss spontaneous ascitic fluid 
infection in the absence of clinical signs and symptoms.  
 
The criteria for diagnosis of spontaneous ascitic fluid infection as well as 
risk factors associated with it in outpatients without clinical or biological 
signs of infection need to be reassessed in larger randomized trials.  
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S.No MGE NO Age Sex Etiology Literacy Alcohol Smoking Albumin No of paracentesis Childs Infection Cell count Culture Ascitic protein
1 6379/09 55 1 1 1 1 2 2.4 1 B 2 2 2 1.2
2 6528/09 53 1 1 1 1 1 2.3 1 B 2 2 2 1.2
3 3765/09 22 2 4 2 2 2 2.8 1 B 2 2 2 1.1
4 3638/09 52 1 1 1 1 1 2.6 1 B 1 2 1 1
5 3768/06 38 2 4 2 2 2 2.7 1 B 2 2 2 1.3
6 5103/09 51 2 2 2 2 2 3 4 C 2 2 2 1.4
7 3063/09 47 1 1 2 1 1 3.1 4 C 2 2 2 1.2
8 4941/09 45 1 1 2 1 1 2.8 4 C 2 2 2 1
9 2192/06 38 1 2 2 2 1 2.4 4 B 2 2 2 1.2
10 1166/05 48 2 4 2 2 2 3 4 B 2 2 2 1.1
11 912/09 56 2 2 2 2 2 2.6 4 B 2 2 2 1.5
12 3295/08 43 2 1 2 1 2 2.9 4 C 2 2 2 1.2
13 650/07 49 1 1 1 1 1 3.4 4 B 2 2 2 1.1
14 3954/09 24 1 1 1 1 2 2.1 4 C 2 2 2 1
15 5989/06 49 2 3 2 2 2 2.4 4 C 2 2 2 1.3
16 3942/09 45 1 1 1 1 1 3 1 B 2 2 2 1.4
17 1517/08 22 1 1 2 1 1 2.4 1 B 2 2 2 1
18 21334 38 1 1 2 1 2 2.4 1 B 2 2 2 1
19 1723/09 24 1 4 2 2 2 3.1 1 B 2 2 2 1.2
20 1558/06 56 1 2 2 2 1 3 1 B 2 2 2 1.1
21 6048/09 50 2 4 2 2 2 3.2 3 B 2 2 2 1
22 2716/07 24 1 1 1 1 2 2.9 3 B 2 2 2 1.4
23 1011/08 32 2 1 1 1 2 2.8 3 C 2 2 2 1
24 6572/09 49 1 4 2 2 2 3.1 3 C 2 2 2 1.3
25 4955/07 52 1 3 2 2 1 3.2 3 C 2 2 2 1
26 4613/09 48 1 2 2 2 2 3 3 B 2 2 2 1.2
27 4302/09 58 1 1 1 1 1 2.3 3 C 2 2 2 1.5
28 5944/09 54 2 2 2 2 2 2.7 3 C 2 2 2 1
29 5458/09 50 2 1 2 1 2 3.1 3 B 2 2 2 1.3
30 5450/09 31 1 1 2 1 1 2.5 3 C 2 2 2 1.4
31 3726/05 52 1 1 2 1 1 2.2 1 B 2 2 2 1
32 5889/09 49 1 2 2 2 1 2.4 1 B 2 2 2 1.1
33 3118/09 51 1 1 1 1 2 2 1 B 2 2 2 1
34 5753/09 28 1 4 2 2 1 2.2 1 B 2 2 2 1.4
35 5550/09 51 1 1 1 1 1 3 1 B 2 2 2 1.3
36 4584/06 54 1 1 1 1 2 2.3 4 C 2 2 2 1
37 6642/09 49 1 2 2 2 2 3.1 4 C 1 2 1 1.3
38 3700/08 60 1 1 2 1 1 3.2 4 C 2 2 2 1.2
39 5999/09 51 1 1 1 1 2 2.9 4 B 2 2 2 1.2
40 5335/09 42 2 2 2 2 2 3.5 4 B 2 2 2 1.1
41 5000/09 36 2 1 1 1 2 3.3 3 B 2 2 2 1
42 5394/03 53 1 2 2 2 1 3.4 3 C 2 2 2 1.4
43 1145/08 47 2 2 2 2 2 2.3 3 C 2 2 2 1
44 736/04 48 2 3 2 2 2 2.3 3 C 1 1 2 1.1
45 3464/08 45 2 2 2 2 2 2.6 3 C 2 2 2 1
46 5901/09 20 1 4 2 2 2 2.9 3 C 2 2 2 1.3
47 7065/07 47 1 1 1 1 1 3 3 B 1 1 2 1.2
48 6349/09 59 1 1 1 1 1 3.2 3 B 2 2 2 1
49 5189/09 45 1 2 2 2 2 2.6 3 B 2 2 2 1.3
50 1421/06 48 1 1 2 1 2 3 3 B 1 1 2 1.2
51 4566/09 56 1 1 1 1 1 3.4 2 B 2 2 2 1.2
52 3224/06 49 1 3 2 2 2 2.6 2 B 2 2 2 1.5
53 5344/09 51 1 1 1 1 1 3 2 B 2 2 2 1.6
54 4888/07 26 1 1 2 1 2 3 2 B 2 2 2 1.3
55 28/08 48 1 2 2 2 1 2.3 2 B 2 2 2 1.4
56 3638/09 52 1 1 1 1 2 2.9 2 B 2 2 2 1
57 215/08 51 2 2 2 2 2 3.3 2 B 2 2 2 1
58 4479/09 54 1 1 2 1 1 2.8 2 C 2 2 2 1.2
59 1468/06 40 1 1 1 1 1 1.9 2 B 2 2 2 1.5
60 3768/06 36 2 4 2 2 2 2.7 2 B 2 2 2 1.2
61 4784/09 55 1 1 2 1 2 2.6 3 C 2 2 2 1
62 4752/09 50 1 1 1 1 1 2.4 3 C 2 2 2 1.1
63 476/06 56 1 1 2 1 1 2.5 3 B 2 2 2 1
64 4080/07 37 1 2 2 2 2 2 3 C 2 2 2 1
65 6185/08 50 1 1 1 1 1 3.1 3 C 2 2 2 1.3
66 1398/09 40 1 2 2 2 1 2.9 3 C 2 2 2 1.2
67 6417/09 52 1 1 2 1 2 3.2 3 B 2 2 2 1
68 796/08 45 1 2 2 2 2 3.4 3 B 2 2 2 1.3
69 1022/05 39 2 2 1 2 2 3.3 3 B 2 2 2 1.2
70 6665/07 57 1 1 1 1 2 3.4 3 B 2 2 2 1.1
71 4054/06 49 2 4 2 2 2 2.3 3 C 2 2 2 1
72 4362/09 56 1 2 2 2 1 3.4 3 B 2 2 2 1.2
73 6557/07 30 1 1 2 1 2 2.7 3 B 2 2 2 1.1
74 801/07 20 1 3 2 2 2 2.8 3 C 2 2 2 1
75 4744/09 51 1 1 1 1 2 2.5 3 C 2 2 2 1.3
76 5092/09 45 1 1 2 1 2 2.6 3 C 2 2 2 1.4
77 5534/07 59 1 3 2 2 2 3.2 3 B 2 2 2 1
78 4036/06 54 1 3 2 2 1 3.4 3 B 2 2 2 1
79 2980/07 53 1 1 1 1 2 2.2 4 C 2 2 2 1.3
80 5971/08 57 1 1 2 1 2 3 4 B 2 2 2 1.4
81 4688/04 53 1 1 1 1 2 2 2 B 2 2 2 1
82 4566/07 50 2 2 2 2 2 3.2 2 B 2 2 2 1.3
83 3412/09 52 1 1 1 1 2 3.1 2 B 2 2 2 1.2
84 1965/05 50 2 3 2 2 2 2.2 2 B 2 2 2 1.5
85 6241/09 35 1 1 2 1 2 2.8 2 B 2 2 2 1
86 4770/08 57 1 1 1 1 2 2.5 2 B 2 2 2 1.3
87 546/09 45 1 2 2 2 2 3.2 2 B 2 2 2 1.4
88 5169/06 52 1 1 2 1 2 3 2 B 2 2 2 1
89 2798/09 37 1 1 1 1 2 2.6 2 B 2 2 2 1.4
90 6744/03 53 2 1 2 1 2 2.4 2 C 2 2 2 1.2
91 2590/06 57 2 4 2 2 2 3 2 B 2 2 2 1.1
92 6320/08 60 1 1 1 1 2 2.4 2 B 2 2 2 1.3
93 6210/09 49 1 1 2 1 2 2.4 2 B 2 2 2 1.5
94 5883/07 45 1 3 1 2 2 3 2 B 2 2 2 1.2
95 2647/09 54 2 4 2 2 2 2.6 2 B 2 2 2 1.1
96 6355/09 47 1 1 2 1 2 2.8 2 B 1 1 2 1
97 5965/07 54 1 1 1 1 1 2.9 2 B 2 2 2 1.3
98 486/08 59 2 2 2 2 2 2.7 2 B 2 2 2 1.4
99 6360/05 55 1 1 2 1 2 2.2 2 B 2 2 2 1.4
100 1103/06 49 2 4 2 2 2 3.1 2 B 2 2 2 1.2
101 3653/06 53 1 1 2 1 2 3.4 2 B 2 2 2 1.2
102 4196/09 55 1 3 2 2 1 2.8 2 B 2 2 2 1.3
103 4108/07 51 1 1 1 1 2 3 2 B 2 2 2 1
104 4545/08 49 2 4 2 2 2 3.1 2 B 2 2 2 1.4
105 5860/07 37 2 2 2 2 2 3.2 2 B 2 2 2 1.4
106 1332/06 52 1 1 1 1 2 2.7 2 B 2 2 2 1
107 2822/07 47 2 4 2 2 2 2.9 2 B 1 1 1 1
108 2248/07 53 1 1 1 1 1 2.5 2 B 2 2 2 1.2
109 1401/09 54 1 1 2 1 1 2.7 2 B 2 2 2 1.3
110 2514/09 56 1 1 2 1 2 2.3 3 C 2 2 2 1
Sex Literacy Infection
Male 1 Yes 1 Yes 1
Female 2 No 2 No 2
Etiology Alcohol
Alcohol 1 Yes 1 Cell count >250 cells/mm3
Hepatitis B 2 No 2 Yes 1
Hepatitis C 3 Smoking No 2
Others 4 Yes 1
No 2 Culture
Positive 1
Negative 2
ABBREVIATIONS 
 
SBP   Spontaneous bacterial peritonitis  
LVP   Large-volume paracentesis 
MNB   Monomicrobial non-neutrocytic bacterascites  
CNNA  Culture-negative neutrocytic ascites 
PMN    Polymorphonuclear  
BT    Bacterial translocation  
GALT   Gut-associated lymphoid tissue  
APC    Antigen presenting cells  
PAMP  Pathogen-associated molecular pattern 
PRR   Pattern recognition receptor 
TLR   Toll like receptor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proforma 
 
Name    Age    Sex 
MGE No: 
Resident   Occupation (Unoccupied [U], specify) 
Literacy    Per capita income  No of family members 
Adults    Children   Religion  
Type of house (Pucca, Semi, Kutcha)   Veg/NV 
Alcohol:Y/N   Duration:   Quantity: (180/360/720) 
Frequency: (daily; alternate; once a week; festival) 
Brand: (Whiskey/Brandy/Country liquor)  Abstainence: 
Height   Weight   BMI 
Diagnosis: (Cirrhosis – Child’s scoring: B  C 
Etiology :( Alcohol; HBV; HCV; Miscellaneous)  Duration: 
Co morbid: 
HT/Duration:   DM/Duration:  Treatment :( OHA/Insulin)
Diagnosed before CLD: CAD:    Past H/O surgery: 
Blood transfusion: 
 
Complications: 
Ascites:   Pedal edema:   UGI bleed: 
SBP:    HE:    Jaundice: 
HCC:    Oliguria: 
 
Duration of symptoms: 
 
Ascites:   Pedal edema:   UGI bleed: 
SBP:    HE:    Jaundice: 
Investigation: 
 
Hb:   TC:   Platelet:   PCV: 
MCV:   MCH:   MCHC:   PT: 
INR:   APTT:  Bl group:   Sugar: 
Urea:   Creatinine:  Bilirubin: (T)   Direct: 
AST:   ALT:   GGT:    SAP:  
Total protein: Albumin:  Globulin:   HBsAg: 
Anti HCV:  AntiHIV: 
Ascitic Fluid: 
 
Protein:  Albumin:  Cell count:   Culture: 
Amylase: 
SAAG:  AFP: 
USG: 
Liver (Shrunken;Coarse/Altered/↑echoes;Irregular):   
 Spleen: 
PV diameter:  PV thrombosis: Collaterals: 
Flow: (Hepatopedal/Hepatofugal)  Ascites:   GSD: 
 
